Reconnect Labs is a Swiss, clinical stage biopharmaceutical company on a mission to disrupt the cycle of illness that underlies mental health conditions. Leveraging decades of expertise and a world-class network of leaders in clinical drug development, Reconnect Labs is progressing the development of rapid-acting precision psychiatry designed drug candidates with the potential to transform the treatment landscape for insomnia and psychiatric conditions such as PTSD and substance use disorders. With our innovative approach to the design of precision therapeutics, and use of digital psychiatry tools as precision diagnostics, we aim to deliver commercially scalable and accessible treatments that will provide both immediate symptom alleviation and durable, long-term, disease modifying therapeutic benefits.